International Patients
Pourquoi nous choisir?
ELZA, une combinaison unique de chirurgiens hautement qualifiés, de physiciennes, et de chercheurs. Ensemble, ils garantissent un traitement optimal.
APPRENEZ PLUS
لماذا نحن؟
مؤسسة «الزا» في سويسرا تضم نخبة مميزة من اطباء عيون متمرسين, فيزيائيين, وباحثين, لكي تزودك بالعلاج الامثل.
اعرف اكثر
با انتخاب ما از چه مزایایی می توانید بهره مند شوید؟
موسسه الزا در کشور سوئیس شامل مجموعه ای از متبحترین چشم پزشکان، متخصصان فیزیک و پژوهشگران می باشد تا بهترین راه حل را برای درمان مشکل شما فراهم نمایند.
طلاعات بیشتر
Почему Вам лучше выбрать нас?
ELZA Institute в Швейцарии – это уникальное сочетание высококвалифицированных офтальмологов, физиков и научных исследователей, которые готовы предоставить Вам самoе лучшее лечение.
УЗНАЙТЕ БОЛЬШЕ
Latest News
Swiss Eye Laser Surgeon among the 100 top most influential people in ophthalmology
The ELZA founder Farhad Hafezi has been voted by his peers onto the Powerlist 2018, a list of the 100 top most influential people in ophthalmology. This is the third ...
Read More
Read More
Awards and Distinctions
Given to ELZA members in the past 20 years for their contributions in ophthalmology.
Swiss Eye Laser Surgeon among the 100 top most influential people in ophthalmology
The ELZA founder Farhad Hafezi has been voted by his peers onto the Powerlist 2018, a list of the 100 top most influential people in ophthalmology. This is the third ...
Read More
Read More
Scientific
Our research laboratory at the University of Zurich
The ELZA co-founder Prof. Farhad Hafezi is running a research laboratory at the University of Zurich, Switzerland. The main foci are corneal biomechanics (keratoconus) and ocular cell biology.
Visit the CABMM’s website here.
Educational
We proudly announce that the second edition of our medical textbook “Corneal Cross-Linking” will soon appear with Slack Inc. The book is edited by ELZA Founder Farhad Hafezi (University of Geneva & USC Los Angeles) and J. Bradley Randleman (USC Los Angeles). It is the oldest and most complete international textbook on cross-linking technology.
Humanitarian
Our International humanitarian initiative
To increase awareness about keratoconus in children.
To disseminate information amongst parents and children.
To treat children with keratoconus in National Reference Sites.
To perform research to identify the causes of keratoconus.
Visit the Light for Sight website here.
Entrepreneurial
ELZA in the global “Top 40 under 40”
We are proud to announce that our co-founder and head of Strategy and BD&L, Nikki Hafezi, MASIP ETHZ, was voted by her peers among the Top 40 under 40 in the British journal “The Ophthalmologist. This list comprises “the most important upcoming personalities in global opthalmology“.
Mrs Hafezi also serves as CEO of EMAGine SA.
See the online version of the PowerList “Top 40 under 40” here, and read the PDF here.
Developing the future of Cross-Linking Technology
ELZA members co-founded a Spin-Off Company: EMAGine SA.
EMAGine SA develops a cross-linking device that will fit on a slit lamp.
The device will allow for treatment outside an operating theatre.
Visit EMAGine’s website here.
ELZA Posts
Swiss Eye Laser Surgeon among the 100 top most influential people in ophthalmology
The ELZA founder Farhad Hafezi has been voted by his peers onto the Powerlist 2018, a list of the 100 ...
More...
More...
ELZA at SAMIR 2018 in Tanger
The ELZA Institute was represented at the 2018 Meeting of the Moroccon Cataract and Refractive Surgeons in Tanger. Prof. Farhad ...
More...
More...
How long does the effect of cross-linking last?
How long does cross-linking last? See this video interview with Farhad Hafezi from the ELZA Institute Background Fifteen years into the ...
More...
More...
ELZA Institute 2017 in numbers
The ELZA Institute looks back at a successful 2017 in clinics, research and education Clinics We have successfully established the ...
More...
More...
Keracon 2017 in Hyderabad
ELZA participates at the 2017 meeting of the Cornea Society of India. Prof. Farhad Hafezi is an invited International Faculty ...
More...
More...
Switzerland’s first Down Syndrome eye consultation
November 10, 2017: Keratoconus affects about 1 in 2,000 people in the general population, but 1 in 7 Down syndrome ...
More...
More...
Categories
Video Interviews
-
Awards
-
Scientific Publications
-
Popular Press
-
Podium Power
-
Search News
